Loading…
Reported covered position: Legislative Assistant and Legislative Director, Rep. Kind
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm:
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
PENNSYLVANIA HIGHER EDUCATION ASSISTANCE AGENCY via BALLARD SPAHR LLP
2020 · first_quarter · Q1
Issues related to Student Loan Programs, Congressional Oversight of Student Loan Financing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) via BALLARD SPAHR LLP
2020 · first_quarter · Q1
Source: Senate LDA
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Suspicious Order Identification Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Suspicious Order Identification Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Prescription Drug Pricing Reduction Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Prescription Drug Pricing Reduction Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Suspicious Order Identification Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Suspicious Order Identification Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Preventing Pill Mills Through Data Sharing Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Preventing Pill Mills Through Data Sharing Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Legislative proposals to amend FARA and H.R.1, provisions relating to restrictions on US subsidiary political engagement.
Legislative proposals to amend FARA and H.R.1, provisions relating to restrictions on US subsidiary political engagement.
Legislative proposals to amend FARA and H.R.1, provisions relating to restrictions on US subsidiary political engagement.
Legislative proposals to amend FARA and H.R.1, provisions relating to restrictions on US subsidiary political engagement.
Elijah E. Cummings Lower Drug Costs Now Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Elijah E. Cummings Lower Drug Costs Now Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress); H.R. 3 Lower Drug Costs Now Act of 2019
Suspicious Order Identification Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Suspicious Order Identification Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress); H.R. 3 Lower Drug Costs Now Act of 2019
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Humanitarian Standards for Individuals in Customs and Border Protection Custody Act
Client: COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) · Firm: BALLARD SPAHR LLP
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Prescription Drug Pricing Reduction Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Prescription Drug Pricing Reduction Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Suspicious Order Identification Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Suspicious Order Identification Act of 2019
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Preventing Pill Mills Through Data Sharing Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Preventing Pill Mills Through Data Sharing Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress); H.R. 3 Lower Drug Costs Now Act of 2019
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Improving Transparency and Accuracy in Medicare Part D Spending Act
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
DEA Order Clearinghouse Act of 2018
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress); H.R. 3 Lower Drug Costs Now Act of 2019
DEA Order Clearinghouse Act of 2018
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
DEA Order Clearinghouse Act of 2018
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
DEA Order Clearinghouse Act of 2018
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
DEA Order Clearinghouse Act of 2018
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
DEA Order Clearinghouse Act of 2018
Client: CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) · Firm: BALLARD SPAHR LLP
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress); H.R. 3 Lower Drug Costs Now Act of 2019
Reform of Government Sponsored Enterprises.
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Filing targets: Federal Housing Finance Agency (FHFA), HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) via BALLARD SPAHR LLP
2020 · first_quarter · Q1
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
THE WORD AND BROWN COMPANIES via BALLARD SPAHR LLP
2020 · first_quarter · Q1
Changes to the Affordable Care Act, including changes to small group health Insurance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBUS MEDICAL, INC. via BALLARD SPAHR LLP
2020 · first_quarter · Q1
Sunshine Act provisions in the Affordable Care Act. Prospective Stark Act changes.
Sunshine Act provisions in the Affordable Care Act. Prospective Stark Act changes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) via BALLARD SPAHR LLP
2019 · fourth_quarter · Q4
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal of safe harbor protection for rebates to plans or PBMs involving prescription pharmaceuticals and creation of new safe harbor protection. International Pricing Index Model. S.2686/ H.R. 4814 Suspicious Order Identification Act of 2019; H.R. 3 Elijah E. Cummings Lower Drugs Costs Now Act; S. 2543 Prescription Drug Pricing Reduction Act of 2019; S. 3070 Preventing Pill Mills Through Data Sharing Act
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FAIR FARA COALITION via BALLARD SPAHR LLP
2019 · fourth_quarter · 4T
Legislative proposals to amend FARA and H.R.1, provisions relating to restrictions on US subsidiary political engagement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PENNSYLVANIA HIGHER EDUCATION ASSISTANCE AGENCY via BALLARD SPAHR LLP
2019 · fourth_quarter · Q4
Issues related to Student Loan Programs, Congressional Oversight of Student Loan Financing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) via BALLARD SPAHR LLP
2019 · fourth_quarter · Q4
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Reform of Government Sponsored Enterprises.
Filing targets: Federal Housing Finance Agency (FHFA), HOUSE OF REPRESENTATIVES, SENATE
THE WORD AND BROWN COMPANIES via BALLARD SPAHR LLP
2019 · fourth_quarter · Q4
Changes to the Affordable Care Act, including changes to small group health Insurance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBUS MEDICAL, INC. via BALLARD SPAHR LLP
2019 · fourth_quarter · Q4
Sunshine Act provisions in the Affordable Care Act. Prospective Stark Act changes.
Sunshine Act provisions in the Affordable Care Act. Prospective Stark Act changes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PENNSYLVANIA HIGHER EDUCATION ASSISTANCE AGENCY via BALLARD SPAHR LLP
2019 · third_quarter · 3A
Issues related to Student Loan Programs, Congressional Oversight of Student Loan Financing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
PENNSYLVANIA HIGHER EDUCATION ASSISTANCE AGENCY via BALLARD SPAHR LLP
2019 · third_quarter · RA
Issues related to Student Loan Program; Congressional oversight of student loan financing.
PENNSYLVANIA HIGHER EDUCATION ASSISTANCE AGENCY via BALLARD SPAHR LLP
2019 · third_quarter · Q3
Issues related to Student Loan Programs, Congressional Oversight of Student Loan Financing
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FAIR FARA COALITION via BALLARD SPAHR LLP
2019 · third_quarter · Q3
Legislative proposals to amend FARA and H.R.1, provisions relating to restrictions on US subsidiary political engagement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) via BALLARD SPAHR LLP
2019 · third_quarter · Q3
Reform of Government Sponsored Enterprises.
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Filing targets: Federal Housing Finance Agency (FHFA), HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) via BALLARD SPAHR LLP
2019 · third_quarter · Q3
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress); H.R. 3 Lower Drug Costs Now Act of 2019
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. International Pricing Index Model.
THE WORD AND BROWN COMPANIES via BALLARD SPAHR LLP
2019 · third_quarter · Q3
Changes to the Affordable Care Act, including changes to small group health Insurance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
GLOBUS MEDICAL, INC. via BALLARD SPAHR LLP
2019 · third_quarter · Q3
Sunshine Act provisions in the Affordable Care Act. Prospective Stark Act changes.
Sunshine Act provisions in the Affordable Care Act. Prospective Stark Act changes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
PENNSYLVANIA HIGHER EDUCATION ASSISTANCE AGENCY via BALLARD SPAHR LLP
2019 · third_quarter · RR
Issues related to Student Loan Program; Congressional oversight of student loan financing.
FAIR FARA COALITION via BALLARD SPAHR LLP
2019 · second_quarter · Q2
Legislative proposals to amend FARA and H.R.1, provisions relating to restrictions on US subsidiary political engagement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) via BALLARD SPAHR LLP
2019 · second_quarter · Q2
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. International Pricing Index Model.
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
GLOBUS MEDICAL, INC. via BALLARD SPAHR LLP
2019 · second_quarter · Q2
Sunshine Act provisions in the Affordable Care Act. Prospective Stark Act changes.
Sunshine Act provisions in the Affordable Care Act. Prospective Stark Act changes.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, SENATE
THE WORD AND BROWN COMPANIES via BALLARD SPAHR LLP
2019 · second_quarter · Q2
Changes to the Affordable Care Act, including changes to small group health Insurance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) via BALLARD SPAHR LLP
2019 · second_quarter · Q2
Reform of Government Sponsored Enterprises.
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Filing targets: Federal Housing Finance Agency (FHFA), HOUSE OF REPRESENTATIVES, SENATE
THE WORD AND BROWN COMPANIES via BALLARD SPAHR LLP
2019 · first_quarter · 1A
Changes to the Affordable Care Act, including changes to group health Insurance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
FAIR FARA COALITION via BALLARD SPAHR LLP
2019 · first_quarter · Q1
Legislative proposals to amend FARA and H.R.1, provisions relating to restrictions on US subsidiary political engagement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) via BALLARD SPAHR LLP
2019 · first_quarter · Q1
Monitor legislation to prevent and reduce prescription drug abuse. Medication Therapy Management. S.988 and H.R. 803, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act, legislation to prohibit Medicare Part D plan sponsors from retroactively reducing payment on clean claims submitted by pharmacies. Pharmaceutical compounding and the implementation of Drug Quality Security Act; S. 3282 and H.R. 6600, the DEA Order Clearinghouse Act of 2018 (legislation from the 115th Congress).
Legislation to ensure more appropriate general payment amount for drugs and biological under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Average Sales Price (ASP) generally (in the context of Deficit Reduction). Policies to exclude cancer drugs from the sequestration cuts. Removal Of Safe Harbor Protection for Rebates to Plans or PBMs Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection. International Pricing Index Model.
THE WORD AND BROWN COMPANIES via BALLARD SPAHR LLP
2019 · first_quarter · Q1
Changes to the Affordable Care Act, including changes to group health Insurance.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) via BALLARD SPAHR LLP
2019 · first_quarter · Q1
Reform of Government Sponsored Enterprises.
Reform of Government Sponsored Enterprises. Dodd-Frank reform measures, including regulatory relief for mid-sized banks and CFPB measures. Implementation of S. 2135 Economic Growth, Regulatory Relief, and Consumer protection Act.
Filing targets: Federal Housing Finance Agency (FHFA), HOUSE OF REPRESENTATIVES, SENATE
FAIR FARA COALITION via BALLARD SPAHR LLP
2019 · first_quarter · RA
Proposals to amend the Foreign Agent Registrations Act
COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) via BALLARD SPAHR LLP
2019 · first_quarter · RA
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) via BALLARD SPAHR LLP
2019 · first_quarter · RA
Medicare reimbursement, drug pricing, prescription drug abuse, and general tax provisions
Medicare reimbursement, drug pricing, prescription drug abuse, and general tax provisions
Medicare reimbursement, drug pricing, prescription drug abuse, and general tax provisions
GLOBUS MEDICAL, INC. via BALLARD SPAHR LLP
2019 · first_quarter · RA
Sunshine Act provisions in the Affordable Care Act; Medical device tax repeal
Sunshine Act provisions in the Affordable Care Act; Medical device tax repeal
Sunshine Act provisions in the Affordable Care Act; Medical device tax repeal
THE WORD AND BROWN COMPANIES via BALLARD SPAHR LLP
2019 · first_quarter · RA
Affordable Care Act and changes to group health insurance
FAIR FARA COALITION via BALLARD SPAHR LLP
2019 · first_quarter · RR
Proposals to amend the Foreign Agent Registrations Act
COFFEE & ASSOCIATES (ON BEHALF OF TEXAS CAPITAL BANK) via BALLARD SPAHR LLP
2019 · first_quarter · RR
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
Reform of Government Sponsored Enterprises, Dodd-Frank reform measures, and Implementation of S.2135, Economic Growth, Regulatory Relief and Consumer Protection Act.
CENCORA, INC. (FORMERLY AMERISOURCEBERGEN CORPORATION) via BALLARD SPAHR LLP
2019 · first_quarter · RR
Medicare reimbursement, drug pricing, prescription drug abuse, and general tax provisions.
Medicare reimbursement, drug pricing, prescription drug abuse, and general tax provisions.
Medicare reimbursement, drug pricing, prescription drug abuse, and general tax provisions.
THE WORD AND BROWN COMPANIES via BALLARD SPAHR LLP
2019 · first_quarter · RR
Affordable Care Act and changes to group health insurance
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
Filing targets: HOUSE OF REPRESENTATIVES, SENATE